Navigation Links
Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
Date:2/25/2008

FRANKFURT, Germany, February 25 /PRNewswire/ -- t2cure, a clinical stage biopharmaceutical company developing novel regenerative therapies based on autologous progenitor cells, announced today that it has appointed Dr. Petra Rueck Head of Clinical Operations.

"We are pleased to have Petra join our company", said Manfred Ruediger, CEO of t2cure. "Petra's experience in clinical research and project management will be of critical importance to t2cure as we are preparing to move our lead product into Phase III clinical trials for severe infarcts."

"It is a unique opportunity to contribute to the development of therapies that have the potential to significantly improve patient outcomes", said Petra Rueck. "t2cure's clinical candidates have demonstrated their capacity to increase the regenerative potential of tissue damaged by acute myocardial infarctions and other cardiac or peripheral vascular diseases."

Prior to joining t2cure, Dr Rueck was a project leader with ratiopharm's Biogenerix AG, Mannheim, where most recently she was responsible for a biotechnology project including the design and management of preclinical and clinical development programs. Her previous experience includes positions in clinical research management at Pfizer and Intervet. Before that, Dr. Rueck was assistant professor at Berlin University Hospital "Benjamin Franklin" (now Charite) and worked as postdoctoral researcher at INSERM, Paris. Petra Rueck received her PhD degree in pharmacology from the University of Giessen, Germany, where she studied veterinary medicine.

About t2cure GmbH

t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease, non-ischemic heart failure, peripheral arterial occlusiv
'/>"/>

SOURCE t2cure GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
2. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
3. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
4. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
5. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
6. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
7. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board
8. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
10. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
11. Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study of ... future storm surge flooding, such as occurred in Hurricane Ike in 2008. , ... protection, Costello also balanced socio-economic and environmental needs and concerns. The team ...
(Date:7/28/2015)... A n ew UK ... and commercialising innovative medicines to transform patient quality of life ... management team; blue chip investor ... Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces that ... from blue chip institutional investors and simultaneously acquired a portfolio ...
(Date:7/28/2015)... , July 28, 2015 People with a ... aids achieved significant and sometimes profound improvements in their ... devices, according to a new multicenter study led by ... the study, described online ahead of print in the journal ... and private clinics in the United States ...
(Date:7/28/2015)... July 21, 2015 Research and Markets ... the "Biomedical Refrigerators and Freezers Market - ... Forecast 2014 - 2022" report to their ... and freezers market has been segmented based on ... banks, and others. The others segment includes applications ...
Breaking Biology Technology:Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 2Biomedical Refrigerators and Freezers Market Report - Global Industry Analysis 2015 3
... a day. So several speakers at the Fusion 2007 CEO-CIO ... point that "work smarter, not harder" is more than just ... of Wisconsin-Madison School of Business, summed it up: "When productivity ... him, producing more by working more hours and giving up ...
... For years I had been focusing on the wrong currency. ... I should have been looking at what they were getting ... Best Buy. , ,It's about time. A large corporation ... vested interest in flexible working (such as those selling IT ...
... the technology associated with his digital product isn't perfect, ... and transform it for the voice-recognition market. , ,Hager, ... , has ambitious plans for his Web-based, voice transcription ... plus self-correction and the ability to work with multiple ...
Cached Biology Technology:Fusion 2007: Innovation drives productivity in post 24x7 world 2How Best Buy said bye to burnout, hello to results 2How Best Buy said bye to burnout, hello to results 3How Best Buy said bye to burnout, hello to results 4How Best Buy said bye to burnout, hello to results 5Tech upstart VoVision could disrupt the voice-recognition market 2Tech upstart VoVision could disrupt the voice-recognition market 3Tech upstart VoVision could disrupt the voice-recognition market 4
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
(Date:7/8/2015)... 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... announced the launch of a study that aims ... Monitoring℠ (PCM) technology for predicting response to treatment ... combination of the novel immunotherapy agents Yervoy® (ipilumumab), ... inhibitor. The 50-patient study will be led by ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... familiarity does not affect the stickleback,s ability to recognize ... thus seems to be the overruling mechanism when it ... Numerous species, from microbes to humans and even ... their kind. However, it has proven remarkably difficult to ...
... that routine screening using a non-invasive test that analyzes ... detect Down,s syndrome and other genetic fetal abnormalities in ... in Obstetrics & Gynecology , the results suggest that ... and could reshape standards in prenatal testing. ...
... PAUL) June 6, 2013 A research team led by ... Jakub Tolar, M.D., Ph.D. from the Masonic Cancer Center, University ... genetic defects in the skin cells of patients with the ... the journal Molecular Therapy and highlighted in the ...
Cached Biology News:Oh brother, where art thou? 2Non-invasive first trimester blood test reliably detects Down's syndrome 2U of M researchers find novel gene correction model for epidermolysis bullosa 2
IgG2b, k APC clone A95-1, Isotype Rat IgG2b, kappa, 0.1 mg ....
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Mouse BLC/BCA 1 - 10kDa...
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
Biology Products: